Autologous hematopoietic stem cell transplant (ASCT) may be curative therapy for pediatric patients with relapsed/refractory Hodgkin lymphoma (HL). Therapy for HL may involve pulmonary toxic modalities. Little information exists regarding pulmonary function in these patients post-ASCT. A retrospective chart review was performed for patients undergoing ASCT from February 2012 to December 2019. Lung disease was defined as a z-score ≤−1.7 in forced expiratory volume in the first second (FEV₁), forced vital capacity (FVC), total lung capacity (TLC), or diffusing capacity of lung for carbon monoxide. Descriptive and limited statistical analyses were performed. Twenty-eight patients were included. Median age at diagnosis was 15 (2 to 19) and was 17 (4 to 21) at ASCT. Twenty-three received radiation before ASCT. Fourteen received brentuximab before, and 9 after, transplant. Nineteen met criteria for lung disease post-ASCT. Sixteen had lung disease before ASCT. Longitudinal trends for pulmonary function testing parameters did not reach statistical significance, however, FEV₁, FVC, and TLC trended towards worsening immediately post-transplant. There was no statistically significant change in FEV₁, FVC, or TLC at 2 years as compared with pretransplant data, suggesting no substantial difference from baseline. Diffusing capacity of lung for carbon monoxide showed statistically significant improvement at the 2 year timepoint (P=0.03). This data reinforces the importance of close follow-up for these patients. Large cohort studies are necessary to identify risk factors so that possible mitigative strategies or alternate regimens could be used.

自体造血干细胞移植（ASCT）可能是复发/难治性霍奇金淋巴瘤（HL）儿科患者的治疗方法。HL 的治疗可能涉及肺部毒性治疗。关于这些患者 ASCT 后肺功能的信息很少。对 2012 年 2 月至 2019 年 12 月期间接受 ASCT 的患者进行了回顾性图表审查。肺部疾病的定义为第一秒用力呼气量 (FEV1)、用力肺活量 (FVC)、总计 z 值_≤ − 1.7肺活量（TLC），或肺的一氧化碳弥散能力。进行了描述性和有限的统计分析。其中包括二十八名患者。诊断时的中位年龄为 15 岁（2 至 19 岁），ASCT 时的中位年龄为 17 岁（4 至 21 岁）。23 人在 ASCT 之前接受了放射治疗。14 人在移植前接受了brentuximab，9 人在移植后接受了 brentuximab。19 人符合 ASCT 后肺部疾病的标准。十六人在 ASCT 前患有肺部疾病。肺功能测试参数的纵向趋势未达到统计学显着性，然而，FEV ₁、FVC和TLC在移植后有立即恶化的趋势。与移植前数据相比，2 年时FEV ₁ 、FVC 或 TLC没有统计学上的显着变化，表明与基线没有显着差异。肺一氧化碳弥散能力在 2 年时间点显示出统计上显着的改善（P = 0.03）。这些数据强调了对这些患者进行密切随访的重要性。有必要进行大型队列研究来确定危险因素，以便可以使用可能的缓解策略或替代方案。